[1] Lyke KE, Atmar RL, Islas CD, et al. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med 2022; 3: 100679. doi: 10.1016/j.xcrm.2022.100679 [2] [3] Grenfell RFQ, Almeida NBF, Filgueiras PS, et al. Immunogenicity, effectiveness, and safety of inactivated virus (CoronaVac) vaccine in a two-dose primary protocol and BNT162b2 heterologous booster in Brazil (Immunita-001): a one year period follow up phase 4 study. Front Immunol 2022; 13: 918896. doi: 10.3389/fimmu.2022.918896 [4] Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 COVID-19 third booster vaccine in Israel. Circulation 2022; 146: 802−804. doi: 10.1161/CIRCULATIONAHA.122.060961 [5] Patone M, Mei XW, Handunnetthi L, et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation 2022; 146: 743−754. doi: 10.1161/CIRCULATIONAHA.122.059970 [6] Le Vu S, Bertrand M, Jabagi MJ, et al. Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. Nat Commun 2022; 13: 3633. doi: 10.1038/s41467-022-31401-5 [7] Yap J, Tham MY, Poh J, et al. Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting. Ann Acad Med Singap 2022; 51: 96−100. doi: 10.47102/annals-acadmedsg.2021425 [8] Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 vaccination and myocarditis in a nordic cohort study of 23 million residents. JAMA Cardiol 2022; 7: 600−612. doi: 10.1001/jamacardio.2022.0583 [9] Koiwaya H, Nishihira K, Tomozoe K, et al. Serial histopathologic assessment of fulminant myocarditis after the first mRNA COVID-19 vaccine dose. Eur Heart J 2022; 43: 1995. doi: 10.1093/eurheartj/ehac083